Please assess the completion status of the following clinical trial:

Trial Title: TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has documented HIV-1 infection~* Treatment with an Antiretroviral regimen (containing at least 2 NRTIs in combination with at least 1 NNRTI and/or 1 PI) for at least 12 weeks~* Plasma HIV-1 RNA \>1000 copies/mL~* General medical condition does not interfere with the assessments and the completion of the trial~Exclusion Criteria:~* Patients for whom an investigational Antiretroviral is part of the current regimen, with the following exceptions if applicable (depending on local regulatory approval)~* tenofovir, emtricitabine, atazanavir, fosamprenavir~* Previous or current use of lopinavir, enfuvirtide (T-20), tipranavir and TMC114~* Life expectancy of less than 6 months~* Pregnant or breast-feeding~* Females of childbearing potential not willing to use effective non-hormonal birth control methods or not willing to continue practicing these birth control methods for at least 14 days after the end of the treatment period~* Patients with significantly decreased liver function or decompensation, irrespective of liver enzyme levels~* Participation in other investigational trials without prior approval of the sponsor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 002 (Type: EXPERIMENTAL): LPV/rtv One 400mg LPV tablet twice daily with 100mg RTV
- 001 (Type: EXPERIMENTAL): TMC114/rtv Two 300mg TMC114 tablets twice daily with 100mg RTV

Based on this trial design, predict the completion outcome and termination type (if applicable).